SI3215193T1 - Dozirna shema za pegiliran interferon - Google Patents
Dozirna shema za pegiliran interferonInfo
- Publication number
- SI3215193T1 SI3215193T1 SI201531980T SI201531980T SI3215193T1 SI 3215193 T1 SI3215193 T1 SI 3215193T1 SI 201531980 T SI201531980 T SI 201531980T SI 201531980 T SI201531980 T SI 201531980T SI 3215193 T1 SI3215193 T1 SI 3215193T1
- Authority
- SI
- Slovenia
- Prior art keywords
- dosage regimen
- pegylated interferon
- pegylated
- interferon
- regimen
- Prior art date
Links
- 102000014150 Interferons Human genes 0.000 title 1
- 108010050904 Interferons Proteins 0.000 title 1
- 229940079322 interferon Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14192114 | 2014-11-06 | ||
PCT/US2015/059410 WO2016073825A1 (en) | 2014-11-06 | 2015-11-06 | Dosage regimen for pegylated interferon |
EP15857703.1A EP3215193B1 (en) | 2014-11-06 | 2015-11-06 | Dosage regimen for pegylated interferon |
Publications (1)
Publication Number | Publication Date |
---|---|
SI3215193T1 true SI3215193T1 (sl) | 2024-02-29 |
Family
ID=51945707
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201531980T SI3215193T1 (sl) | 2014-11-06 | 2015-11-06 | Dozirna shema za pegiliran interferon |
Country Status (30)
Country | Link |
---|---|
US (2) | US11559567B2 (sl) |
EP (2) | EP3215193B1 (sl) |
JP (2) | JP6820841B2 (sl) |
KR (2) | KR20230079520A (sl) |
CN (1) | CN107530403A (sl) |
AU (1) | AU2015342908B2 (sl) |
BR (1) | BR112017009193A2 (sl) |
CA (1) | CA2964390A1 (sl) |
CL (1) | CL2017001088A1 (sl) |
DK (1) | DK3215193T3 (sl) |
EA (1) | EA037151B1 (sl) |
ES (1) | ES2966888T3 (sl) |
FI (1) | FI3215193T3 (sl) |
HK (1) | HK1243627A1 (sl) |
HR (1) | HRP20231732T1 (sl) |
HU (1) | HUE064909T2 (sl) |
IL (1) | IL251627B (sl) |
LT (1) | LT3215193T (sl) |
MX (1) | MX2017005244A (sl) |
MY (1) | MY191506A (sl) |
NZ (1) | NZ730924A (sl) |
PH (1) | PH12017500617A1 (sl) |
PL (1) | PL3215193T3 (sl) |
PT (1) | PT3215193T (sl) |
RS (1) | RS65015B1 (sl) |
SG (1) | SG11201702798PA (sl) |
SI (1) | SI3215193T1 (sl) |
TW (1) | TWI737583B (sl) |
WO (1) | WO2016073825A1 (sl) |
ZA (1) | ZA201702704B (sl) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190374611A1 (en) * | 2017-01-18 | 2019-12-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment patients suffering from myeloproliferative disorders |
US11414698B2 (en) * | 2018-03-22 | 2022-08-16 | Chang Gung Medical Foundation Chang Gung Memorial Hospital At Chiayi | Method of quantifying mutant allele burden of target gene |
CN115968291A (zh) * | 2020-04-22 | 2023-04-14 | 南湖制药公司 | 聚乙二醇化干扰素tau及其组合物和方法 |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5382657A (en) * | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5951974A (en) | 1993-11-10 | 1999-09-14 | Enzon, Inc. | Interferon polymer conjugates |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US5738846A (en) * | 1994-11-10 | 1998-04-14 | Enzon, Inc. | Interferon polymer conjugates and process for preparing the same |
US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
TW517067B (en) * | 1996-05-31 | 2003-01-11 | Hoffmann La Roche | Interferon conjugates |
US6824768B2 (en) * | 1998-12-18 | 2004-11-30 | Schering Corporation | Ribavirin-pegylated interferon alfa induction HCV combination therapy |
BR0013252A (pt) * | 1999-08-13 | 2002-04-16 | Hoffmann La Roche | Micofenolato mofetila em associação com peg-ifn-alfa |
IL147581A0 (en) | 1999-08-27 | 2002-08-14 | Maxygen Aps | New interferon beta-like molecules |
CA2390292A1 (en) | 1999-11-12 | 2001-05-25 | Maxygen Holdings Ltd. | Interferon gamma conjugates |
US7125843B2 (en) | 2001-10-19 | 2006-10-24 | Neose Technologies, Inc. | Glycoconjugates including more than one peptide |
US20030171285A1 (en) | 2001-11-20 | 2003-09-11 | Finn Rory F. | Chemically-modified human growth hormone conjugates |
MXPA04004809A (es) | 2001-11-20 | 2004-08-11 | Pharmacia Corp | Conjugados de hormona de crecimiento humana modificada quimicamente. |
GEP20074024B (en) | 2002-01-18 | 2007-01-10 | Biogen Idec Inc | Polyalkylene glycol comprising a radical for conjugation of biologically active compound |
US7345150B2 (en) | 2002-03-26 | 2008-03-18 | Medical University Of Toledo | Albumin-based colloid composition having at least one protected thiol region, methods of making, and methods of use |
JP4764630B2 (ja) | 2002-09-09 | 2011-09-07 | ネクター セラピューティックス | 水溶性ポリマーアルカナール |
US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
RS20050501A (en) | 2002-12-26 | 2007-08-03 | Mountain View Pharmaceuticals Inc., | Polymer conjugates of cytokines,chemokines,growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity |
TR201907313T4 (tr) | 2003-05-23 | 2019-06-21 | Nektar Therapeutics | İki PEG zinciri içeren PEG türevleri. |
KR20060120141A (ko) | 2003-11-24 | 2006-11-24 | 네오스 테크놀로지스, 인크. | 글리코페질화 에리트로포이에틴 |
AP2007003919A0 (en) | 2004-08-31 | 2007-02-28 | Pharmacia & Upjohn Co Llc | Glycerol branched polyethylene glycol human growthhormone conjugates, process for their prepation a nd methods of use thereof |
US7365127B2 (en) | 2005-02-04 | 2008-04-29 | Enzon Pharmaceuticals, Inc. | Process for the preparation of polymer conjugates |
WO2006094530A1 (en) | 2005-03-11 | 2006-09-14 | Siegfried Ltd. | Di-polymer protein conjugates and processes for their preparation |
CN101002944B (zh) | 2006-01-17 | 2012-07-25 | 中国科学院过程工程研究所 | 支链聚乙二醇-干扰素结合物及其制备方法 |
EP1834963A1 (en) | 2006-03-13 | 2007-09-19 | Siegfried Ltd. | Di-polymer protein conjugates and processes for their preparation |
CN101104078B (zh) | 2006-07-11 | 2011-11-02 | 北京美倍他药物研究有限公司 | 多肽及蛋白药物的聚乙二醇偶合物 |
CN101108895B (zh) | 2006-07-19 | 2011-10-26 | 北京键凯科技有限公司 | 聚乙二醇乙醛衍生物及其与药物的结合物 |
US20090035273A1 (en) | 2006-08-18 | 2009-02-05 | Pepgen Corporation | Combination treatment method with interferon-tau |
CN1966547B (zh) | 2006-11-06 | 2011-11-09 | 中国药科大学 | 双链结构的聚乙二醇衍生物的制备及其与药物分子的结合 |
CN1970572A (zh) | 2006-12-21 | 2007-05-30 | 北京三元基因工程有限公司 | 干扰素α突变体及其聚乙二醇衍生物 |
CL2008002399A1 (es) | 2007-08-16 | 2009-01-02 | Pharmaessentia Corp | Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c. |
ES2382124T3 (es) | 2007-09-04 | 2012-06-05 | Biosteed Gene Expression Tech. Co., Ltd. | Interferón alfa 2b modificado con polietilenglicol y método de preparación y aplicaciones de este |
DK2196475T3 (da) | 2007-09-04 | 2012-09-17 | Biosteed Gene Expression Tech Co Ltd | Interferon alfa 2a, som er modificeret med polyethylenglycol, fremgangsmåde til syntese deraf samt anvendelse deraf |
CN101491682A (zh) | 2008-04-30 | 2009-07-29 | 北京凯正生物工程发展有限责任公司 | 聚乙二醇化重组人干扰素ω偶合物及其制备工艺 |
UA104146C2 (ru) | 2008-07-31 | 2014-01-10 | Фармаиссеншиа Корп. | ПОЛИМЕРНЫЕ КОНЪЮГАТЫ ФРАГМЕНТОВ ИНТЕРФЕРОНА-β, ЭРИТРОПОЭТИНА И ГОРМОНА РОСТА |
CN101671390B (zh) | 2008-09-10 | 2012-10-03 | 海南四环心脑血管药物研究院有限公司 | 人干扰素α衍生物及其聚乙二醇化修饰物的制备和用途 |
CN101514229B (zh) | 2009-04-03 | 2012-05-09 | 海南四环心脑血管药物研究院有限公司 | 人干扰素α衍生物及其聚乙二醇化修饰物 |
UA109646C2 (uk) * | 2009-12-10 | 2015-09-25 | Терапевтичне застосування кон'югатів білка з полімером | |
CN103328038A (zh) | 2010-12-01 | 2013-09-25 | 史拜诺莫度雷森公司 | 向神经解剖结构直接递送药剂 |
-
2015
- 2015-11-06 PL PL15857703.1T patent/PL3215193T3/pl unknown
- 2015-11-06 EP EP15857703.1A patent/EP3215193B1/en active Active
- 2015-11-06 NZ NZ730924A patent/NZ730924A/en unknown
- 2015-11-06 TW TW104136693A patent/TWI737583B/zh active
- 2015-11-06 HR HRP20231732TT patent/HRP20231732T1/hr unknown
- 2015-11-06 FI FIEP15857703.1T patent/FI3215193T3/fi active
- 2015-11-06 SI SI201531980T patent/SI3215193T1/sl unknown
- 2015-11-06 EP EP23199969.9A patent/EP4282485A3/en active Pending
- 2015-11-06 HU HUE15857703A patent/HUE064909T2/hu unknown
- 2015-11-06 DK DK15857703.1T patent/DK3215193T3/da active
- 2015-11-06 MY MYPI2017701335A patent/MY191506A/en unknown
- 2015-11-06 LT LTEPPCT/US2015/059410T patent/LT3215193T/lt unknown
- 2015-11-06 ES ES15857703T patent/ES2966888T3/es active Active
- 2015-11-06 BR BR112017009193-3A patent/BR112017009193A2/pt not_active Application Discontinuation
- 2015-11-06 KR KR1020237018405A patent/KR20230079520A/ko not_active Application Discontinuation
- 2015-11-06 PT PT158577031T patent/PT3215193T/pt unknown
- 2015-11-06 AU AU2015342908A patent/AU2015342908B2/en active Active
- 2015-11-06 JP JP2017519649A patent/JP6820841B2/ja active Active
- 2015-11-06 MX MX2017005244A patent/MX2017005244A/es unknown
- 2015-11-06 WO PCT/US2015/059410 patent/WO2016073825A1/en active Application Filing
- 2015-11-06 KR KR1020177015233A patent/KR102540109B1/ko active IP Right Grant
- 2015-11-06 RS RS20231262A patent/RS65015B1/sr unknown
- 2015-11-06 EA EA201790991A patent/EA037151B1/ru unknown
- 2015-11-06 US US15/518,423 patent/US11559567B2/en active Active
- 2015-11-06 CN CN201580058159.1A patent/CN107530403A/zh active Pending
- 2015-11-06 SG SG11201702798PA patent/SG11201702798PA/en unknown
- 2015-11-06 CA CA2964390A patent/CA2964390A1/en active Pending
-
2017
- 2017-04-04 PH PH12017500617A patent/PH12017500617A1/en unknown
- 2017-04-06 IL IL251627A patent/IL251627B/en unknown
- 2017-04-18 ZA ZA2017/02704A patent/ZA201702704B/en unknown
- 2017-05-02 CL CL2017001088A patent/CL2017001088A1/es unknown
-
2018
- 2018-02-24 HK HK18102667.8A patent/HK1243627A1/zh unknown
-
2020
- 2020-09-10 JP JP2020151877A patent/JP2021001184A/ja not_active Withdrawn
-
2022
- 2022-12-23 US US18/088,272 patent/US20230131552A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201702891B (en) | Interferon alpha 2b variants | |
GB201713653D0 (en) | Dosage regimen | |
HRP20181572T1 (hr) | Režim doziranja spoja fgf-18 | |
GB201521217D0 (en) | Dosage regimens | |
HK1243627A1 (zh) | 用於長效型干擾素的劑量方案 | |
GB201418710D0 (en) | Dosage regimen | |
IL266255A (en) | New dosage regimen | |
ZA201800217B (en) | Novel dosage regimen tiacumicin compound | |
HRP20181406T1 (hr) | Farmaceutski dozni oblici | |
GB201617850D0 (en) | Dosage regimen | |
GB201610502D0 (en) | Dosage regimen | |
GB201521216D0 (en) | Dosage regimen | |
GB201418708D0 (en) | Dosage regimen | |
GB201400171D0 (en) | Dosage regimen | |
GB201411345D0 (en) | Nicotine dosage regimen |